Exciting Developments in GABAB Positive Allosteric Modulators
Addex Therapeutics (SIX/NASDAQ: ADXN), a leader in developing innovative small molecule allosteric modulators for neurological disorders, has announced a significant advancement with its partner Indivior. Together, they have successfully moved the GABAB positive allosteric modulator (PAM) program through the crucial IND enabling studies. This marks an important step for the treatment landscape in addressing substance use disorders.
Progress in Preclinical Studies
According to Tim Dyer, CEO of Addex, Indivior's dedication to enhancing the GABAB PAM program has yielded impressive results. They have completed critical preclinical safety and toxicity studies using a compound identified from their collaborative research. This accomplishment not only underscores the technical expertise of Addex’s research team but also enhances the potential for future treatments targeting substance use disorders.
Progress on Multiple Fronts
Addex is not resting on its laurels; it is also advancing its own GABAB PAM program aimed at chronic cough treatment. The plan is to commence IND enabling studies later this year, further broadening the scope of their research and potential therapeutic applications.
Details of the Collaboration
The partnership between Addex and Indivior is structured to maximize opportunities for both parties. The agreement stipulates potential earnings of up to USD 330 million for Addex, contingent upon meeting defined regulatory, clinical, and commercial milestones. In addition, Addex can earn tiered royalties based on net sales, demonstrating the mutual benefit derived from this collaboration.
Role of GABAB PAM in Treatment
Understanding the role of PAMs in treatment is crucial. Activation of the gamma-aminobutyric acid subtype B (GABAB) receptor has proven clinically effective across various disorder spectrums, including alcoholism and chronic cough. Unlike traditional agonists like baclofen, which can lead to tolerance and other side effects, PAMs are designed to enhance receptor responses only when the natural ligand, GABA, is present. This selective approach may yield better patient outcomes with fewer adverse effects.
About Addex Therapeutics’ Mission
At its core, Addex Therapeutics is committed to pioneering therapies aimed at neurological conditions. Their flagship drug, dipraglurant, is under investigation for its potential benefits in brain recovery after injuries such as strokes. The collaboration with Indivior on the GABAB PAM program signifies a step forward in clinical research aimed at making impactful changes in patients’ lives.
Investment in Future Innovations
Beyond the current programs, Addex also holds a 20% stake in Neurosterix LLC, a spin-out focused on developing additional allosteric modulators. This breadth of research exemplifies Addex’s commitment to expanding treatment options for neurological disorders, which remains a critical area of need in modern medicine.
Language and Contact Information
If you want to learn more about Addex Therapeutics’ innovative approaches and ongoing projects, you can visit their website for additional resources. For direct inquiries, you can reach out to:
Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
Email: PR@addextherapeutics.com
Mike Sinclair
Partner, Halsin Partners
Telephone: +44 (0)7968 022075
Email: msinclair@halsin.com
Frequently Asked Questions
What milestone has Addex achieved with Indivior?
Addex and its partner Indivior have successfully advanced the GABAB PAM program through IND enabling studies, which are critical before initiating clinical trials.
What is the significance of GABAB PAM?
GABAB PAMs are designed to enhance the effects of GABA at the receptor level, which could lead to fewer side effects compared to traditional agonists.
How does the Addex and Indivior collaboration benefit Addex?
Addex stands to gain up to USD 330 million in potential payments based on reaching various development and sales milestones as part of the partnership.
What is the role of PAMs in treating chronic cough?
PAMs enhance natural receptor responses, potentially offering an effective treatment avenue for conditions like chronic cough with fewer side effects.
Where can I find more information about Addex Therapeutics?
Visit the official website of Addex Therapeutics to explore their portfolio and latest research initiatives more extensively.
